Dr. Mihir Pradipkumar Raval, MD, MPH

Dr. Raval practices at Albany Medical Center in Albany, New York, part of Albany Med Health System.

Dr. Raval's NPI, 1962639427, was assigned on June 11, 2009. Dr. Raval holds New York license 292894.

Dr. Raval's primary practice is Albany Medical Center, at 43 New Scotland Avenue, Mail Code 34, Albany, NY 12208 in Albany County. The practice phone is (518) 262-2400.

Dr. Raval's primary practice is Albany Medical Center in Albany, New York, part of Albany Med Health System. Dr. Raval is also affiliated with Samaritan Hospital. The medical group on file is New York Oncology Hematology. Dmand AI also links Dr. Raval to 3 more hospitals and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Raval practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Raval's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Raval is licensed in New York.

CMS data shows 38,406 Medicare services from Dr. Raval across 56 procedure codes in 2024, for 555 Medicare patients. Medicare paid $914,075 for them.

CMS counts 555 Medicare patients who saw Dr. Raval in 2024. The largest group is 65 to 74, with 231 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.23, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Raval's median patient age at 65, with 51% women.

In 2024, Dr. Raval wrote 2,777 Medicare Part D claims for 284 patients. 73% of them were for generic drugs. CMS names the drug for 2,341 of them, across 55 drugs with 11 or more claims each, at $7,334,080 in total drug cost. In 2023, CMS named 1,921 claims across 58 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Raval for performance year 2024, reported as part of a group. Dr. Raval accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Raval as offering telehealth.

Dmand AI links 20 papers to Dr. Raval, published from 2010 to 2025. 2019 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized and Diagnosis, Differential. Dr. Raval has published most often in BMJ Case Rep. Dr. Raval's most frequent co-authors are Rangaswamy Akhanda Chintapatla, MD, Michelle A. Fanale, MD and Tatyana A. Feldman, MD.

Dmand AI links Dr. Raval to 4 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Hodgkin Disease.

CMS Open Payments shows 593 general payments to Dr. Raval from 32 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. AstraZeneca Pharmaceuticals LP paid the most, $135,771.